CardioVascular BioTherapeutics, Inc.

CardioVascular BioTherapeutics, Inc., a development stage biopharmaceutical company, focuses on developing and marketing protein drug candidates used in the treatment of cardiovascular disease. The company uses an active pharmaceutical ingredient, the 141 acidic human form of fibroblast growth factor-1, in its drug candidates, which facilitates the growth of new blood vessels in the heart tissues and organs with an impaired vascular system. Its products under development include CVBT-141A, a Phase I clinical trial completed product for use in the treatment of severe coronary heart disease; and CVBT-141B, a Phase I clinical trial completed product for the treatment of wound healing; CVBT-141C, a Phase I clinical trial product for the treatment of peripheral artery disease; and CVBT-141H, a Phase I clinical trial product for the treatment of severe coronary heart disease. The company’s pre-clinical research and development stage products comprise CVBT-141E for the treatment of lumbar ischemia, and CVBT-141F for bone repair. In addition, CardioVascular BioTherapeutics’ product portfolio includes CVBT-141D, which is under proof of concept clinical trials stage for the treatment of disc ischemia. The company was founded in 1998. It was formerly known as CardioVascular Genetic Engineering, Inc. and changed its name to CardioVascular BioTherapeutics, Inc. in 2004. The company is headquartered in Las Vegas, Nevada.